Latest Insider Transactions at Apellis Pharmaceuticals, Inc. (APLS)
This section provides a real-time view of insider transactions for Apellis Pharmaceuticals, Inc. (APLS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Apellis Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Apellis Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 22
2024
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,431
-4.02%
|
$873,015
$65.0 P/Share
|
|
Jan 22
2024
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,413
-3.49%
|
$221,845
$65.0 P/Share
|
|
Jan 22
2024
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
4,184
-3.83%
|
$271,960
$65.0 P/Share
|
|
Jan 22
2024
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
2,593
-3.66%
|
$168,545
$65.0 P/Share
|
|
Jan 22
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,551
-3.58%
|
$230,815
$65.0 P/Share
|
|
Jan 22
2024
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,607
-2.38%
|
$104,455
$65.0 P/Share
|
|
Jan 22
2024
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
1,738
-3.24%
|
$112,970
$65.0 P/Share
|
|
Jan 22
2024
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,061
-2.64%
|
$68,965
$65.0 P/Share
|
|
Jan 22
2024
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
1,384
-2.07%
|
$89,960
$65.0 P/Share
|
|
Jan 22
2024
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,913
-0.35%
|
$254,345
$65.0 P/Share
|
|
Jan 17
2024
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
5,207
-7.17%
|
$338,455
$65.58 P/Share
|
|
Jan 17
2024
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
3,276
-5.75%
|
$212,940
$65.58 P/Share
|
|
Jan 16
2024
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
864
-2.11%
|
$57,024
$66.81 P/Share
|
|
Jan 16
2024
|
James George Chopas VP/Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,312
+16.86%
|
-
|
|
Jan 16
2024
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,632
-0.15%
|
$107,712
$66.81 P/Share
|
|
Jan 16
2024
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,743
+0.6%
|
-
|
|
Jan 16
2024
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
1,857
-2.55%
|
$122,562
$66.81 P/Share
|
|
Jan 16
2024
|
Nur Nicholson Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,508
+21.14%
|
-
|
|
Jan 16
2024
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
1,631
-2.38%
|
$107,646
$66.81 P/Share
|
|
Jan 16
2024
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,963
+19.83%
|
-
|
|
Jan 16
2024
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
1,632
-2.79%
|
$107,712
$66.81 P/Share
|
|
Jan 16
2024
|
Karen Lewis Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,963
+22.46%
|
-
|
|
Jan 16
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,235
-2.2%
|
$147,510
$66.81 P/Share
|
|
Jan 16
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,748
+18.97%
|
-
|
|
Jan 16
2024
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,235
-2.23%
|
$147,510
$66.81 P/Share
|
|
Jan 16
2024
|
Adam J. Townsend Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,748
+19.17%
|
-
|
|
Jan 16
2024
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
4,240
-3.74%
|
$279,840
$66.81 P/Share
|
|
Jan 16
2024
|
David O. Watson General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
23,748
+17.3%
|
-
|
|
Jan 16
2024
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,851
-2.3%
|
$518,166
$66.81 P/Share
|
|
Jan 16
2024
|
Cedric Francois Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
72,094
+17.42%
|
-
|
|
Jan 16
2024
|
Caroline Baumal Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,445
+30.36%
|
-
|
|
Jan 16
2024
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
438
-0.6%
|
$28,908
$66.81 P/Share
|
|
Jan 16
2024
|
Jeffrey Eisele Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,508
+21.07%
|
-
|
|
Jan 04
2024
|
Caroline Baumal Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,751
-7.71%
|
$165,060
$60.05 P/Share
|
|
Jan 01
2024
|
Gerald Chan Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,341
+22.61%
|
-
|
|
Jan 01
2024
|
Stephanie Monaghan O'Brien Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,341
+22.61%
|
-
|
|
Jan 01
2024
|
Paul R. Fonteyne Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,341
+16.89%
|
-
|
|
Jan 01
2024
|
Alec Machiels Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,341
+0.89%
|
-
|
|
Jan 01
2024
|
A. Sinclair Dunlop Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,341
+2.47%
|
-
|
|
Dec 27
2023
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
235
-0.44%
|
$14,100
$60.23 P/Share
|
|
Dec 26
2023
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
68
-0.13%
|
$3,876
$57.86 P/Share
|
|
Dec 19
2023
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
3,905
-2.11%
|
$222,585
$57.19 P/Share
|
|
Dec 19
2023
|
David O. Watson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
7,905
+7.78%
|
$102,765
$13.85 P/Share
|
|
Dec 14
2023
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,274
+4.65%
|
$81,562
$13.19 P/Share
|
|
Dec 01
2023
|
Lukas Scheibler Chief Research Officer |
SELL
Open market or private sale
|
Direct |
10,000
-12.77%
|
$600,000
$60.0 P/Share
|
|
Dec 01
2023
|
Lukas Scheibler Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+11.33%
|
$130,000
$13.85 P/Share
|
|
Dec 01
2023
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
110,000
-35.98%
|
$6,600,000
$60.91 P/Share
|
|
Dec 01
2023
|
Adam J. Townsend Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
110,000
+37.11%
|
$1,650,000
$15.09 P/Share
|
|
Dec 01
2023
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
24,000
-11.08%
|
$1,464,000
$61.13 P/Share
|
|
Nov 30
2023
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
14,158
-7.73%
|
$764,532
$54.76 P/Share
|